SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc. (OTCBB:AEMD), a pioneer in developing therapeutic devices for infectious disease, announced today that research related to the Aethlon Hemopurifier® as a potential treatment for Ebola Hemorrhagic Fever (EHF) has been initiated at The Centers for Disease Control and Prevention (CDC). EHF is classified as a category "A" bioterror threat presently untreatable with antiviral drug and vaccine therapy. According to the World Health Organization (WHO), EHF causes death in 50-90% of all clinically ill cases. The CDC is recognized globally for its research initiatives to prevent and control infectious disease. It operates as a primary component of the Department of Health and Human Services (HHS), the principal agency in the United States government for protecting the health and safety of all Americans.
